NCL ICB are commissioning a programme of work from January 2025 to March 2026, to review patients with CKD stages G3a-G5 who could be prescribed an SGLT2 inhibitor, but who are not currently prescribed the medication. This intervention will be beneficial to the patient’s health and self-management of their condition. A SOP was published and shared with PCN leads in early March to describe this programme of work further.

SGLT-2i used appropriately in CKD can impact significantly on both the rates of heart attacks and strokes in these patients, but also to reduce the number who reach end-stage kidney disease and renal replacement therapy. 

To support this work, join a one-hour interactive session with experts from the NCL Chronic Kidney Disease Integrated Service.

Learn about:

• The benefits to prescribing an SGLT-2 inhibitor in CKD when appropriate; for both patients and the wider healthcare system
• How suitable patients have been identified through searches and who should be focused on
• The updated NCL CKD Pathway (launched January 2025) recommendations for using SGLT-2i in CKD